CAS Number: 162359-56-0

Formula: C19H34ClNO2

Molecular Weight: 343.93 g/mol

Method of Analysis: In house

Application: Treatment of Relapsing-Remitting MS Fingolimod is an immunomodulating drug, mostly used for treating multiple sclerosis. In clinical trials, it has reduced the rate of relapses in relapsing-remitting multiple sclerosis by approximately one-half over a two-year period

Mechanism: In vivo, fingolimod is phosphorylated to form fingolimod-phosphate, which resembles naturally occurring sphingosine 1-phosphate (S1P). S1P exerts diverse physiological actions by activating its cognate G protein-coupled receptors. These receptors are expressed on a wide range of cells that are involved in many biological processes relevant to MS. These receptors have 5 types. Type 1 (S1P1) plays a key role in the immune system, regulating lymphocyte egress from lymphoid tissues into the circulation. Fingolimod-phosphate initially activates lymphocyte S1P1 via high-affinity receptor binding yet subsequently induces S1P1 down-regulation that prevents lymphocyte egress from lymphoid tissues, thereby reducing auto aggressive lymphocyte infiltration into the central nervous system (CNS). S1P receptors are also expressed by many CNS cell types and have been shown to influence cell proliferation, morphology, and migration. Fingolimod crosses the blood-brain barrier and may therefore have direct CNS effects, distinguishing it from immunologically targeted MS therapies

Packaging: 1th polyethylene plastic bag. 2th. Three layered aluminum foil

Storage conditions: Store in a refrigerator in a well-closed container